Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02831387
Recruitment Status : Terminated
First Posted : July 13, 2016
Last Update Posted : August 11, 2017
Information provided by (Responsible Party):
Parion Sciences

Brief Summary:
The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

Condition or disease Intervention/treatment Phase
Dry Eye Disease Drug: P-321 Ophthalmic Solution Drug: P-321 Ophthalmic Solution placebo Phase 2

Detailed Description:
This is a multi-center, randomized, double-masked, placebo-controlled, parallel group Phase 2b trial designed to evaluate symptoms and signs in subjects with mild to moderate dry eye disease. Eligible patients, will be treated with placebo during 2-week placebo run-in period. Subjects will then be randomly assigned in a double-masked, 1:1 ratio to either 0.017% P-321 Ophthalmic Solution or placebo TID for 28 days. This study is designed to evaluate the changes in symptoms. Safety will be assessed throughout the study by adverse events.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Study Start Date : July 2016
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Diseases

Arm Intervention/treatment
Experimental: 0.017% P-321 Ophthalmic Solution
0.017% P-321 Ophthalmic Solution TID for 28 days.
Drug: P-321 Ophthalmic Solution
P-321 Ophthalmic Solution 0.017%
Other Name: P-321

Placebo Comparator: Placebo
P-321 Ophthalmic Solution Placebo TID for 28 days.
Drug: P-321 Ophthalmic Solution placebo
Placebo to match P-321 Ophthalmic Solution
Other Name: Placebo

Primary Outcome Measures :
  1. Change from baseline (Visit 2) to Day 29 (Visit 4) in the subject-completed symptom questionnaire. [ Time Frame: 29 days ]

Secondary Outcome Measures :
  1. Change from baseline (Visit 2) to Day 29 in total symptom scores [ Time Frame: 29 days ]
  2. Change from baseline to day 29 in total fluorescein and Lissamine green staining of the cornea and conjunctiva, respectively. [ Time Frame: 29 days ]
  3. The proportion of subjects with at least a 20% improvement from baseline to Day 29 in symptom scores [ Time Frame: 29 days ]
  4. The proportion of subjects with at an improvement following 14 and 28 days of treatment in symptom scores [ Time Frame: 28 days ]
    Changes from baseline to Day 15 will also be assessed.

  5. Safety will be assess by the number of AEs from screening to Day 28 [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent
  2. Male or female subjects aged 18 to 80 years, inclusive
  3. Have a history of dry eye disease (DED) in both eyes
  4. Be on stable regimens of other needed medications
  5. Have a BCVA of +0.7 or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS)
  6. Have reported symptoms
  7. Have the following sings in at least one eye: Schirmer score without anesthesia of >1 and <10 mm at 5 minutes and staining of conjunctival and corneal areas of the eye.
  8. Have normal lid anatomy

Exclusion Criteria:

  1. Have undergone refractive eye surgery in the past 12 months
  2. Have undergone previous eyelid surgery in either eye (External blepharoplasty not resulting in exposure or abnormal blinking is allowed)
  3. Have lid irregularities or deformities
  4. Have a history of glaucoma, a history of an elevated lOP within the past year, or an lOP in either eye > 25 mmHg at the Screening Visit (Visit 1)
  5. Have any clinically significant, uncontrolled, or unstable medical or surgical conditions that could affect his or her ability to participate
  6. Have permanent punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction. Removable punctal plugs are allowed if they have been used regularly for at least 60 days prior to the screening visit. However, if a plug comes out during the study it must be promptly replaced.
  7. Have clinical findings of severe Meibomian Gland Dysfunction (MGD) in the Study Eye
  8. Are pregnant or breast feeding
  9. Use of any investigational product or device within 28 days prior to the Screening Visit or during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02831387

United States, California
Sall Research Medical Center
Artesia, California, United States, 90701
United States, Missouri
Tauber Eye Center
Kansas City, Missouri, United States, 64111
Ophthalmology Associates
Saint Louis, Missouri, United States, 63131
Comprehensive Eye Care, Ltd.
Washington, Missouri, United States, 63090
United States, North Carolina
UNC Kittner Eye Center
Chapel Hill, North Carolina, United States, 27517
United States, Texas
Ocular Surface Center, Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Virginia
Virginia Eye Consultants
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Parion Sciences

Responsible Party: Parion Sciences Identifier: NCT02831387     History of Changes
Other Study ID Numbers: P-321-202
First Posted: July 13, 2016    Key Record Dates
Last Update Posted: August 11, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Conjunctival Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Ophthalmic Solutions